Zora Biosciences

Zora Biosciences is a privately held, commercial-stage diagnostics company based in Espoo, Finland, founded in 2007. The company has developed a proprietary mass spectrometry platform to identify ceramide and phospholipid biomarkers for cardiometabolic risk assessment. Its flagship products, CERT2 for cardiovascular risk and dSCORE for type 2 diabetes risk, are validated and available, with a test for fatty liver disease in development. Zora's strategy leverages partnerships, including with Mayo Clinic, and its own lab services to drive adoption of its novel risk stratification tools.

Proprietary high-throughput mass spectrometry platform for the quantification of lipid biomarkers, specifically ceramides and phospholipids, coupled with bioinformatics to generate clinical risk scores.

Zora competes in the specialized niche of lipidomics-based diagnostics. While traditional lab companies offer standard cholesterol panels, Zora's direct competitors are other diagnostics firms leveraging mass spectrometry and omics technologies for risk prediction (e.g., companies focused on proteomic or metabolic signatures). Its early focus and strong publication record on ceramides provide a defensible position, but the field is attracting increasing interest.